Skip to content
Ochre Bio logo

Ochre Bio

Ochre Bio is a YC Winter 2020 (W20) company. Based in Oxford, England, United Kingdom. Team of 50.

  • Biotech
  • Genomics

About Ochre Bio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Ochre Bio develops RNA medicines for chronic liver diseases, conditions that currently have few effective treatment options. The company combines AI with human liver data and human tissue models to discover and validate disease pathways, replacing the reliance on animal models and less disease-specific datasets that have historically limited liver drug development.

Go-to-market

Ochre Bio works with large pharmaceutical companies, including GSK, Boehringer Ingelheim, and Takeda, which access its proprietary human liver datasets and AI-generated disease models through research partnerships as a path toward co-developing novel liver therapeutics.

From the Y Combinator listing

How Ochre Bio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

RNA medicines for liver diseases

Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Oxford, England, United Kingdom
Team size
50
Status
Active
Stage
Growth

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works